The Pentagon's Defense Advanced Research Projects Agency (DARPA) is pushing forward with its development of powdered blood, a potentially revolutionary solution for battlefield medical emergencies. Successfully tested in animals, the technology now faces the complex challenge of scaling for practical military use by 2029.
Battlefield Blood Shortages Rise as Priorities Shift
Military strategists are increasingly concerned about access to fresh blood in future conflicts. The protracted war in Ukraine and the possibility of engagements in remote Pacific locations have highlighted the logistical challenges of evacuating wounded troops. Traditional methods rely on rapid air evacuation within the "golden hour," but such luxuries may not be feasible in contested environments where air superiority is uncertain.
"We've had success in a petri dish. We've had success in animals now," said Lt. Cmdr. Robert Murray, a Navy doctor overseeing DARPA's FSHARP program. "This is truly disruptive technology."
DARPA's powdered blood solution, stored in durable dual-chamber bags, can be quickly mixed with sterile water on-site, providing whole blood that surpasses the efficiency of separately stored blood components. This innovation aims to fill the critical gap in hemorrhage treatment, where immediate access to blood can mean the difference between life and death.
Regulatory Hurdles Loom Large
Despite its promise, the technology must navigate stringent FDA approval processes and manufacturing challenges before reaching troops. Military medical readiness remains a pressing issue, with experts warning of catastrophic casualties in high-intensity conflicts. Retired Air Force Colonel Jeremy W. Cannon projected that up to 1,000 US troops could be killed or wounded daily in a Pacific-based war, with many preventable deaths resulting from inadequate medical infrastructure.
DARPA is now seeking partners to accelerate FDA review and ensure the powdered blood can meet the demands of modern warfare.